Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes    » A1c    » Adolescents    » Awareness    » Cause    » Children    » Complications    » Control    » Costs    » Cure    » Diagnosis    » Drugs    » Elderly    » Gestational    » Hypoglycemia    » Impaired Fasting Glucose    » Impaired Glucose Tolerance    » Inflammation    » Insulin Resistance    » Insulin Sensitivity    » Men    » Metabolic Syndrome    » Minorities    » Obesity    » Organs    » Other Diseases    » Pancreas    » Pre-Diabetes    » Prevention    » Research    » Risk Factors    » Screening    » Statistics    » Stress    » Syndrome X    » Testing    » Treatments    » Type 1    » Type 2    » Warning Signs    » Women Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

About Diabetes » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

TZD’s Connected to Vision-Threatening Complication Posted: Wednesday, April 15, 2009

Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)—a common complication that can lead to vision loss, reports a study.

Liraglutide Has Low CVD Risk but May Be Blocked for Approval Posted: Wednesday, April 15, 2009

Tumor data may block approval for diabetes drug liraglutide. An FDA advisory panel declined to recommend approval for the investigational diabetes drug liraglutide (Victoza), in light of animal studies linking the injection to thyroid cancer.

The Next DPP-4 Inhibitor Onglyza™ Passes CVD Review: Coming Soon Posted: Wednesday, April 15, 2009

An FDA panel voted 10-2 that the investigational diabetes drug saxagliptin (Onglyza) does not put Type 2 diabetes patients at an increased risk for cardiovascular events, but wants drugmaker Bristol-Myers Squibb to conduct long-term postmarketing studies to test the drug in older and sicker patients.

Understanding Barriers to Diabetes Self-Care Helps Providers Empower Patients Posted: Wednesday, April 15, 2009

Despite the provision of comprehensive management programs, patients are often unable to achieve the desired outcomes. It is essential to understand the barriers to diabetes self-care in order to promote successfully self-care behaviors."

New Link Between Obesity and Insulin Resistance Uncovered Posted: Saturday, April 11, 2009

The high BCAA protein levels found in obese individuals, combined with high fat diets, could significantly increase the incidence of pre-diabetic insulin resistance. Because obesity and diabetes are so closely linked, this finding could go a long way in explaining the cause and effect of the obesity-diabetes connection, as well as lay the foundations for future preventative treatments for diabetes in obese individuals.

Brown Fat Could Help Treat Obesity and Diabetes Posted: Friday, April 10, 2009

Brown fat, which helps use energy and burn calories, and was previously believed to only to exist in babies, has recently been shown to occur in adults as well. The discovery of the presence of this "good fat" in adults lays foundations for potential obesity and diabetes treatments that stimulate brown fat growth.

Two New Diabetes Drugs could be Approved by April 2nd Posted: Thursday, March 26, 2009

A U.S. Food and Drug Administration panel will review two proposed drugs to treat Type 2 diabetes this April. According to a meeting notice posted on the FDA's website Monday, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will discuss Bristol-Myers Squibb's saxagliptin tablets on April 1 and Novo Nordisk.'s liraglutide injection on April 2.

Bariatric Surgery Causes Most Cases of Type 2 to Remit Long-Term Posted: Thursday, March 26, 2009

In morbidly obese patients with Type 2 diabetes, bariatric surgery leads to resolution or improvement of the disease in close to 90% of cases, with benefits usually maintained for at least 2 years, according to a meta-analysis.

FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes Posted: Thursday, March 26, 2009

The FDA recommended that manufacturers developing new drugs and biologics for Type 2 diabetes provide evidence that the therapy will not increase the risk of such cardiovascular events as a heart attack. The recommendation is part of a new guidance for industry that applies to all diabetes drugs currently under development.

South Asians More at Risk for Diabetic Retinopathy Posted: Tuesday, March 24, 2009

A recent study out of England has concluded that South Asians are significantly more likely to suffer from diabetic retinopathy than Caucasian Europeans. This is troubling news, especially for the densely populated, and highly diabetic, country of India.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.